Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment

Janet Neisewander, Irwin Lucki, Paul McGonigle

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Rats treated chronically with reserpine develop spontaneous oral dyskinesia. The present study examined the development of the oral dyskinesia during the course of reserpine treatment, and its persistence after termination of treatment. Rats were injected with either reserpine (1 mg/kg, s.c.) or vehicle once daily for 4 days and then every other day for 6 weeks. Oral dyskinesia developed rapidly, reaching a maximal level after 3 days. It persisted at a maximal level for up to 20 days after termination of reserpine treatment, and continued to persist above control level for at least 60 days. The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats. In contrast to the oral dyskinesia, this altered sensitivity to SKF-38393 returned to normal within 20 days after terminating the reserpine treatment, suggesting that these two behavioral responses involve different neural mechanisms. Quantitative autoradiographic measurement of dopamine receptor subtypes revealed that both D1 and D2 receptors were increased in the caudate-putamen (Cpu) and nucleus accumbens. Only the increase in D2 receptor density in the CPu correlated with the persistence of the oral dyskinesia; both changes persisted following termination of the reserpine treatment, and their magnitude was less at 60 days than at 1 and 20 days post-treatment. These results may have important implications for tardive dyskinesia.

Original languageEnglish (US)
Pages (from-to)27-35
Number of pages9
JournalBrain Research
Volume558
Issue number1
DOIs
StatePublished - Aug 30 1991
Externally publishedYes

Fingerprint

Reserpine
Movement Disorders
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
Therapeutics
Caudate Nucleus
Putamen
Dopamine Receptors
Nucleus Accumbens
Injections

Keywords

  • Caudate-putamen
  • Dopamine receptor
  • Oral dyskinesia
  • Rat
  • Reserpine

ASJC Scopus subject areas

  • Developmental Biology
  • Molecular Biology
  • Clinical Neurology
  • Neuroscience(all)

Cite this

Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. / Neisewander, Janet; Lucki, Irwin; McGonigle, Paul.

In: Brain Research, Vol. 558, No. 1, 30.08.1991, p. 27-35.

Research output: Contribution to journalArticle

@article{23c252aa6f3d4188b24c92fcee43b329,
title = "Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment",
abstract = "Rats treated chronically with reserpine develop spontaneous oral dyskinesia. The present study examined the development of the oral dyskinesia during the course of reserpine treatment, and its persistence after termination of treatment. Rats were injected with either reserpine (1 mg/kg, s.c.) or vehicle once daily for 4 days and then every other day for 6 weeks. Oral dyskinesia developed rapidly, reaching a maximal level after 3 days. It persisted at a maximal level for up to 20 days after termination of reserpine treatment, and continued to persist above control level for at least 60 days. The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats. In contrast to the oral dyskinesia, this altered sensitivity to SKF-38393 returned to normal within 20 days after terminating the reserpine treatment, suggesting that these two behavioral responses involve different neural mechanisms. Quantitative autoradiographic measurement of dopamine receptor subtypes revealed that both D1 and D2 receptors were increased in the caudate-putamen (Cpu) and nucleus accumbens. Only the increase in D2 receptor density in the CPu correlated with the persistence of the oral dyskinesia; both changes persisted following termination of the reserpine treatment, and their magnitude was less at 60 days than at 1 and 20 days post-treatment. These results may have important implications for tardive dyskinesia.",
keywords = "Caudate-putamen, Dopamine receptor, Oral dyskinesia, Rat, Reserpine",
author = "Janet Neisewander and Irwin Lucki and Paul McGonigle",
year = "1991",
month = "8",
day = "30",
doi = "10.1016/0006-8993(91)90710-D",
language = "English (US)",
volume = "558",
pages = "27--35",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment

AU - Neisewander, Janet

AU - Lucki, Irwin

AU - McGonigle, Paul

PY - 1991/8/30

Y1 - 1991/8/30

N2 - Rats treated chronically with reserpine develop spontaneous oral dyskinesia. The present study examined the development of the oral dyskinesia during the course of reserpine treatment, and its persistence after termination of treatment. Rats were injected with either reserpine (1 mg/kg, s.c.) or vehicle once daily for 4 days and then every other day for 6 weeks. Oral dyskinesia developed rapidly, reaching a maximal level after 3 days. It persisted at a maximal level for up to 20 days after termination of reserpine treatment, and continued to persist above control level for at least 60 days. The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats. In contrast to the oral dyskinesia, this altered sensitivity to SKF-38393 returned to normal within 20 days after terminating the reserpine treatment, suggesting that these two behavioral responses involve different neural mechanisms. Quantitative autoradiographic measurement of dopamine receptor subtypes revealed that both D1 and D2 receptors were increased in the caudate-putamen (Cpu) and nucleus accumbens. Only the increase in D2 receptor density in the CPu correlated with the persistence of the oral dyskinesia; both changes persisted following termination of the reserpine treatment, and their magnitude was less at 60 days than at 1 and 20 days post-treatment. These results may have important implications for tardive dyskinesia.

AB - Rats treated chronically with reserpine develop spontaneous oral dyskinesia. The present study examined the development of the oral dyskinesia during the course of reserpine treatment, and its persistence after termination of treatment. Rats were injected with either reserpine (1 mg/kg, s.c.) or vehicle once daily for 4 days and then every other day for 6 weeks. Oral dyskinesia developed rapidly, reaching a maximal level after 3 days. It persisted at a maximal level for up to 20 days after termination of reserpine treatment, and continued to persist above control level for at least 60 days. The reserpine-treated rats also exhibited stereotypy in response to acute injection of the D1-selective agonist SKF-38393 (10 mg/kg), which was not observed in control rats. In contrast to the oral dyskinesia, this altered sensitivity to SKF-38393 returned to normal within 20 days after terminating the reserpine treatment, suggesting that these two behavioral responses involve different neural mechanisms. Quantitative autoradiographic measurement of dopamine receptor subtypes revealed that both D1 and D2 receptors were increased in the caudate-putamen (Cpu) and nucleus accumbens. Only the increase in D2 receptor density in the CPu correlated with the persistence of the oral dyskinesia; both changes persisted following termination of the reserpine treatment, and their magnitude was less at 60 days than at 1 and 20 days post-treatment. These results may have important implications for tardive dyskinesia.

KW - Caudate-putamen

KW - Dopamine receptor

KW - Oral dyskinesia

KW - Rat

KW - Reserpine

UR - http://www.scopus.com/inward/record.url?scp=0025808110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025808110&partnerID=8YFLogxK

U2 - 10.1016/0006-8993(91)90710-D

DO - 10.1016/0006-8993(91)90710-D

M3 - Article

VL - 558

SP - 27

EP - 35

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -